G
GeoVax Labs, Inc. (GOVX)
NCM – Real vaqt narxi. Valyuta: USD
1.37
-0.11 (-7.43%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.37
-0.11 (-7.43%)
Yopilishda: May 12, 2026, 4:00 PM EDT
GeoVax Labs, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Qo'shma Shtatlarda yangi patentlangan platformalardan foydalangan holda yuqumli kasalliklar va qattiq o'smalarga qarshi inson vaksinalari va immunoterapiyasini ishlab chiqadi. Kompaniya (COVID-19), OITS (OIV); Zika virusi; bezgak; va Ebola, Sudan, Marburg va Lassa kabi gemorragik isitma viruslariga qarshi turli profilaktik vaksinalarni, shuningdek, OIV, surunkali gepatit B infektsiyalari va qattiq o'smalar uchun terapevtik vaksinalarni ishlab chiqmoqda. U, shuningdek, profilaktik COVID-19 ni davolash uchun 2-bosqich klinik sinovlarda bo'lgan GEO-CM04S1 nomli vaktsina nomzodini; qattiq o'smalarni davolash uchun yangi patentlangan mahsulot/texnologiya bo'lgan Gedeptin va ilg'or bosh va bo'yin yassi hujayrali karsinomani davolash uchun 1/2-bosqich klinik sinovlarini; va pan-koronavirus vaktsinasi bo'lgan GEO-CM02 ni ishlab chiqmoqda. Bundan tashqari, kompaniya qattiq o'smalarni davolash uchun preklinik sinovlarda bo'lgan vaktsina nomzodi GEO-MVA-MUC1; Zika virusini davolash uchun preklinik sinovlarda bo'lgan vaktsina nomzodi GEO-ZM02; Ebola Zaire ni davolash uchun preklinik sinovlarda bo'lgan GEO-EMO1-Z; Ebola Sudan ni davolash uchun preklinik sinovlarda bo'lgan GEO-EMO1-S; Marburgni davolash uchun GEO-MM01; va maymunchechak va chechakni davolash uchun GEO-MVA ni taklif etadi. Milliy sog'liqni saqlash institutlarining Allergik va yuqumli kasalliklar milliy instituti; AQSh Mudofaa vazirligi; va Burnet instituti bilan hamkorlik va hamkorlik shartnomalariga ega. GeoVax Labs, Inc. 1988 yilda ro'yxatga olingan va shtab-kvartirasi Jorjiya shtatining Smyrna shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Harriet Latham Robinson Ph.D. | Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board |
| Dr. John W. Sharkey Ph.D. | Vice President of Business Development |
| Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Medical Officer |
| Dr. Mark J. Newman Ph.D. | Chief Scientific Officer |
| Mr. David Alan Dodd | Chairman, President & CEO |
| Mr. Jeffrey Welch | Head of Process Development & Manufacturing Operations |
| Mr. Mark W. Reynolds CPA | CFO & Corporate Secretary |
| Mr. Thomas O'Brien | Vice President of Quality Systems & Compliance |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-08 | PRER14A | govx-20251231.htm |
| 2026-05-07 | 8-K | govx20260507_8k.htm |
| 2026-04-27 | DEF 14A | govx20260421_def14a.htm |
| 2026-04-17 | POS EX | govx20260417c_posex.htm |
| 2026-04-16 | PRE 14A | govx20260412_pre14a.htm |
| 2026-04-16 | POS AM | govx-20251231.htm |
| 2026-04-15 | 8-K | govx20260415_8k.htm |
| 2026-03-31 | NT 10-K | govx20260330_nt10k.htm |
| 2026-03-31 | 8-K | govx20260331_8k.htm |
| 2026-02-17 | 8-K | govx20260217_8k.htm |